Skip to content

Reported May 7, 2026 · After market close

Next report

Aug 6, 2026 (in a month)
EPS estimate-$0.30

Financials

Q1 2026

Income statement

See full
Revenue--100%
Gross profit--100%
Operating income-$23.5M-54.6%
Net income-$22.2M-130%
EPS (diluted)-$0.32-117%

Balance sheet

See full
Cash & equivalents$34.8M-84.7%
Total equity$116.2M-47.6%
Total assets$127.2M-45.6%

Cash flow

See full
Operating cash flow-$22.2M-87.2%
CapEx--100%
Free cash flow-$22.2M-78.9%

Valuation & ratios

Valuation

as of 07/02/26
See full
Market cap$226.49M

Returns & leverage

See full
Return on equity-68.5%-86.2pp
Current ratio11.4×-7.6×

Segments

By segment

See full
Reportable--100%

Versus estimates

Ask the moment Whitehawk Therapeutics, Inc. Common Stock reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Whitehawk Therapeutics, Inc. Common Stock report Q1 2026 earnings?
Whitehawk Therapeutics, Inc. Common Stock (WHWK) reported Q1 2026 earnings on May 7, 2026 after market close.
What were Whitehawk Therapeutics, Inc. Common Stock's Q1 2026 revenue and EPS?
Whitehawk Therapeutics, Inc. Common Stock reported revenue of - and diluted EPS of $-0.32 for Q1 2026.
Did Whitehawk Therapeutics, Inc. Common Stock beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.36 by $0.04.
How did Whitehawk Therapeutics, Inc. Common Stock's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $7.1M a year earlier and diluted EPS grew 11.1% from $-0.36.
Where can I find Whitehawk Therapeutics, Inc. Common Stock's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-210615) and the 10-Q periodic report (0001193125-26-212075) directly on SEC EDGAR. The filing index links above go to sec.gov.